A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES

吗替麦酚酯治疗先天性尿路病的初步研究

• 批准号: 7608227
• 负责人: HOWARD TRACHTMAN
• 金额: $ 0.34万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608227
• 关键词: Adult; Child; Clinical; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Inflammatory; Institution; Kidney; Kidney Diseases; Mediator of activation protein; Patients; Pilot Projects; Renal function; Research; Research Personnel; Resources; Source; Testing; Therapeutic immunosuppression; United States National Institutes of Health; design; mycophenolate mofetil; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Emerging evidence suggests that inflammatory mediators that infiltrate the kidney in children with congenital uropathies contribute to the progressive decline in kidney function that is observed in these patients. The strategy of using immunosuppressive therapy to protect against progressive, primary non-immunological forms of kidney disease has never been tested in clinical practice involving children or adult patients. This study is designed to test the hypothesis that administration of mycophenolate mofetil (MMF) to children with congenital uropathies will be safe and well tolorated and may prevent the progressive decline of kidney function in patients with congenital uropathies.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 新兴的证据表明，先天性尿液病儿童中肾脏的炎症介质有助于这些患者观察到的肾脏功能的逐步下降。 在涉及儿童或成年患者的临床实践中，使用免疫抑制疗法来预防肾脏疾病的进行性，原发性非免疫学形式的策略从未进行过测试。 这项研究旨在检验以下假设：对先天性尿症患者的霉酚酸酯（MMF）给予安全且耐受性良好，并可能阻止先天性尿症患者肾功能的逐渐下降。